Cue Biopharma, Inc.
CUE
$0.7767
$0.00831.08%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 9.29M | 9.53M | 8.30M | 7.02M | 5.49M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.29M | 9.53M | 8.30M | 7.02M | 5.49M |
| Cost of Revenue | 37.99M | 41.70M | 42.19M | 43.31M | 42.50M |
| Gross Profit | -28.71M | -32.17M | -33.89M | -36.29M | -37.01M |
| SG&A Expenses | 12.89M | 13.47M | 14.25M | 14.99M | 14.98M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 50.88M | 55.17M | 56.44M | 58.30M | 57.48M |
| Operating Income | -41.59M | -45.64M | -48.15M | -51.28M | -51.99M |
| Income Before Tax | -40.67M | -44.61M | -46.96M | -49.97M | -50.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.67 | -44.61 | -46.96 | -49.97 | -50.73 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.67M | -44.61M | -46.96M | -49.97M | -50.73M |
| EBIT | -41.59M | -45.64M | -48.15M | -51.28M | -51.99M |
| EBITDA | -41.20M | -45.23M | -47.70M | -50.80M | -51.44M |
| EPS Basic | -0.75 | -0.91 | -0.97 | -1.07 | -1.11 |
| Normalized Basic EPS | -0.47 | -0.57 | -0.61 | -0.66 | -0.69 |
| EPS Diluted | -0.75 | -0.91 | -0.97 | -1.07 | -1.11 |
| Normalized Diluted EPS | -0.47 | -0.57 | -0.61 | -0.66 | -0.69 |
| Average Basic Shares Outstanding | 225.11M | 198.07M | 193.20M | 187.82M | 183.01M |
| Average Diluted Shares Outstanding | 225.11M | 198.07M | 193.20M | 187.82M | 183.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |